Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "CE"

9359 News Found

AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility
News | January 12, 2026

AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility

Supports production of AbbVie's current and next-generation immunology and neuroscience medicines


PharmaForceIQ acquires Aktana, launches first “optichannel-in-a-box” platform for pharma
News | January 12, 2026

PharmaForceIQ acquires Aktana, launches first “optichannel-in-a-box” platform for pharma

The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement


Evotec subsidiary bags Gates Foundation grant to expand global access to biologics
News | January 12, 2026

Evotec subsidiary bags Gates Foundation grant to expand global access to biologics

The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats


NAMSA expands US footprint with Labcorp medical device testing acquisition
News | January 12, 2026

NAMSA expands US footprint with Labcorp medical device testing acquisition

The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof


Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
Biotech | January 11, 2026

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism


Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
Clinical Trials | January 11, 2026

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial

DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases


Revvity and Lilly partner to accelerate AI drug discovery models
Digitisation | January 10, 2026

Revvity and Lilly partner to accelerate AI drug discovery models

Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering


AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit
People | January 10, 2026

AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030


Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer
Clinical Trials | January 09, 2026

Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer

The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2